News|Articles|February 26, 2025

Pharma Pulse 2/26/25: Real World Data Use in Clinical Development, Gaps in Diabetes Patient Education & more

The latest news for pharma industry insiders.

SCOPE Summit 2025: Shakthi Kumar Talks Real-World Data Use in Clinical Development

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, Edetek, provides examples of how Agentic AI can accelerate clinical development.

Gaps in Diabetes Patient Education and Rising Healthcare Costs

Although the importance of ongoing education is known for patients, less than half of those with diabetes receive formal instruction on managing their condition.

CVS Health Ordered to Comply With FTC Demand for Records

A federal judge in Washington ordered CVS Health Corp. to comply with a document request from the US Federal Trade Commission, a win for the antitrust and consumer protection agency in its long-running conflict with drug benefits middlemen.

ReAlta Life Sciences Announces Appointment of Biotechnology Leader Andrew Miller, PhD, to Board of Directors

Dr. Miller brings extensive experience in biotechnology leadership, drug development, and corporate strategy, having previously founded Karuna Therapeutics, a biopharmaceutical company developing treatments for psychiatric and neurological conditions. He most recently served as President of Research and Development at Karuna until its $14 billion acquisition by Bristol Myers Squibb in 2024.

Rebecca Lowell Edwards on LinkedIn

Thanks for the opportunity to share some thoughts, Miranda Schmalfuhs

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.